newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

  • Eikon Therapeutics (NASDAQ: EIKN) announced that Chairman & CEO Roger M. Perlmutter will participate in a KOL event on August 20, 2026, at 9:00 AM ET.
  • The event is hosted by Cantor Fitzgerald \& features Dr. Timothy A. Yap, a medical oncologist from the University of Texas MD Anderson Cancer Center.
  • Dr. Yap serves as Vice President \& Head of Clinical Development at UT MD Anderson \& is an expert in PARP inhibitors \& DNA damage response strategies.
  • Dr. Yap receives compensation as an advisor to Eikon, a relationship disclosed to UT MD Anderson's Conflict of Interest Committee.
  • Discussions will cover the therapeutic landscape of PARP inhibition in breast, ovarian, prostate, \& pancreatic cancer, including outcomes \& limitations of current agents.
  • Imogen Mansfield will host the event, with an archived webcast available at investors.eikontx.com for 30 days post-event.
  • Eikon is a late-stage clinical biopharmaceutical company focusing on oncology \& utilizing a proprietary single molecule tracking system for drug development.
  • The press release includes standard forward-looking statements regarding product candidates, data readouts, \& financial performance subject to risks such as funding needs \& development failures.
  • Investor contacts include CFO Alfred "Freddie" Bowie, Ph.D. (ir@eikontx.com), \& media contact Colin Sanford (colin@bioscribe.com).